-
Member
-
Originally Posted by Absolute144
Balance,it.must.be.the.cannabis.smoke.wafting.thro ugh.from.the.ASX
Haha - market must be getting a waft as well of the cannabis?
Cannot just have the exChairman and exCEO selling out of their shares (ie. smoking the cannabis per your analogy) at these levels?
-
Member
4 years is a good tenure for a CEO these days. I agree with Balance, responsible officers cannot just dump their stock when they leave. If you look at what he has done in the past , its been about start up, and move on. Now, hes probably got substantial holdings in Wholly Bagels, and Promisia... and is off looking for the next iron in the fire....
Just my opinion.
-
Valuation coming back to something reasonable. Depending on how Q1 sales look relative to Q4 I'm thinking it might be worth buying a few more. New CEO needs to be solid but realistically we're not looking for the next Jack Welch - just someone competent with some marketing/retail/supply chain experience.
Felix, qui potest rerum cognoscere causas
-
Originally Posted by Balance
First the Chairman stepped down, and then resigned as a director shortly after.
May 2016 : "Mr Malcolm Johnson, Chairman of Promisia Integrative Limited has stepped down
as the Company's Chairman. Mr Johnson said "The Company has a clear strategic direction and an exciting
product in Arthrem which already has a considerable following and is capable of aiding many more arthritis sufferers with other products in the pipeline". Mr Johnson commented that the Company had a bright future and that during his three year tenure he had put in place a suite of best practice governing documents which would stand the Company in good stead."
Then, the CEO steps down.
If there is more upside, why would they be resigning?
Wonder if they are selling or have already gotten rid of some of their shares to cash in on the millions of dollars of gains they are sitting on?
https://www.nzx.com/companies/PIL/announcements/299990
Hmmmm - 24% decline in 1Q 17 sales vs 4Q 16 sales.
There goes the growth story.
-
Originally Posted by Balance
"The quarterly sales of $643,588 were up by 169% from the same period in 2016."
The growth story has not gone entirely.
However, I agree the departure of the CEO and Chairman is a major concern until we see news of replacements and the planned new products and Australia launch, there is a HUGE need for caution around this company as indicated by the Market's 50% reduction in the SP from last years highs.
-
Member
I sold out as there is a competitive product available at half the price
-
Originally Posted by Left field
"The quarterly sales of $643,588 were up by 169% from the same period in 2016."
The growth story has not gone entirely.
However, I agree the departure of the CEO and Chairman is a major concern until we see news of replacements and the planned new products and Australia launch, there is a HUGE need for caution around this company as indicated by the Market's 50% reduction in the SP from last years highs.
The quarter that sales go backwards from a previous quarter is when the company will be marked down by investors whose definition of growth stock is one of sales increases consecutively quarter to quarter.
Too coincidental that CEO and Chairman decided to 'retire/quit' imo.
Last edited by Balance; 19-04-2017 at 04:51 PM.
-
Originally Posted by horus1
I sold out as there is a competitive product available at half the price
Hi Horus, what is it called? I did try Promisia but got no benefit.
-
Originally Posted by airedale
Hi Horus, what is it called? I did try Promisia but got no benefit.
Arthri-Remedy - 120 capsules $40.60 vs Arthrem $89.99 180 capsules
Both state their capsules contain herbal extract Artemisia Annua.
Note : Arthrem does state that around 75% of users get relief - that's actually high for a herbal relief.
Posting Permissions
- You may not post new threads
- You may not post replies
- You may not post attachments
- You may not edit your posts
-
Forum Rules
|
|
Bookmarks